西高院(688334.SH):主導的核電領域科技成果順利通過中機聯行業鑑定
格隆匯7月8日丨西高院(688334.SH)在投資者互動平臺表示,核電領域,公司大力開展研究開發,公司主導的核電領域科技成果順利通過中機聯行業鑑定,實現了核電領域的高壓限流熔斷器產品的技術突破。新能源領域,公司主要開展風電、光電、儲能等新能源設備的檢測業務,已建成 7.5MW 大容量光儲變流器電性能測試平臺、儲能電站電池抽檢試驗平臺、RT-LAB 仿真測試平臺並獲取 CNAS/CMA 資質,在新能源領域的檢測能力達到國內領先。固態電池領域,待相關在建項目完成後,公司將擁有電化學儲能電池、新能源汽車動力蓄電池(含固態電池)的檢測能力,後續公司將持續加強技術積累、拓寬檢測服務的應用領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.